Fibrinolysis and the risk of venous and arterial thrombosis

Current Opinion in Hematology

Volumn 14, Issue 3, 2007, Pages 242-248

  Meltzer, Mirjam E ^a,b   Doggen, Carine J M ^b   De Groot, Philip G ^a   Rosendaal, Frits R ^b   Lisman, Ton ^a  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^b LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Arterial thrombosis; Fibrinolysis; Risk factors; Venous thrombosis

Indexed keywords

ANTIFIBRINOLYTIC AGENT; PLASMINOGEN; PLASMINOGEN ACTIVATOR INHIBITOR 1; THROMBIN; THROMBIN ACTIVATABLE FIBRINOLYSIS INHIBITOR; TISSUE PLASMINOGEN ACTIVATOR;

ANGINA PECTORIS; ARTERY THROMBOSIS; BLOOD CLOTTING DISORDER; FIBRINOLYSIS; GENETIC POLYMORPHISM; HEART INFARCTION; HETEROZYGOSITY; HOMOZYGOSITY; HUMAN; NUCLEOTIDE SEQUENCE; PLASMINOGEN DEFICIENCY; PRIORITY JOURNAL; REVIEW; RISK FACTOR; STROKE; VEIN THROMBOSIS;

EID: 34247137477     PISSN: 10656251     EISSN: 15317048     Source Type: Journal    
DOI: 10.1097/MOH.0b013e3280dce557     Document Type: Review

References (66)

1. Rosendaal FR. Venous thrombosis: a multicausal disease. Lancet 1999; 353:1167-1173.
2. Bajzar L, Manuel R, Nesheim ME. Purification and characterization of TAFI, a thrombin-activable fibrinolysis inhibitor. J Biol Chem 1995; 270:14477-14484.
3. Brandt JT. Plasminogen and tissue-type plasminogen activator deficiency as risk factors for thromboembolic disease. Arch Pathol Lab Med 2002; 126:1376-1381.
4. Tefs K, Gueorguieva M, Klammt J, et al. Molecular and clinical spectrum of type I plasminogen deficiency: a series of 50 patients. Blood 2006; 108:3021-3026. A comprehensive description of clinical and laboratory features of a relatively large series of patients with plasminogen deficiency showing that impaired secretion of mutant molecules is largely responsible for the deficiency.
5. Okamoto A, Sakata T, Mannami T, et al. Population-based distribution of plasminogen activity and estimated prevalence and relevance to thrombotic diseases of plasminogen deficiency in the Japanese: the Suita Study. J Thromb Haemost 2003; 1:2397-2403.
6. Ridker PM, Vaughan DE, Stampfer MJ, et al. Baseline fibrinolytic state and the risk of future venous thrombosis: a prospective study of endogenous tissue-type plasminogen activator and plasminogen activator inhibitor. Circulation 1992; 85:1822-1827.
7. Crowther MA, Roberts J, Roberts R, et al. Fibrinolytic variables in patients with recurrent venous thrombosis: a prospective cohort study. Thromb Haemost 2001; 85:390-394.
8. Oguzulgen IK, Ekim N, Erkekol FO, et al. Is tissue-plasminogen activator gene polymorphism a risk factor for venous thromboembolism in every population? J Thromb Thrombolysis 2005; 19:61-63.
9. Hooper WC, Lally C, Austin H, et al. The role of the t-PA I/D and PAI-1 4G/5G polymorphisms in African-American adults with a diagnosis of myocardial infarction or venous thromboembolism. Thromb Res 2000; 99:223-230.
10. Thogersen AM, Jansson JH, Boman K, et al. High plasminogen activator inhibitor and tissue plasminogen activator levels in plasma precede a first acute myocardial infarction in both men and women: evidence for the fibrinolytic system as an independent primary risk factor. Circulation 1998; 98:2241-2247.
11. Thogersen AM, Soderberg S, Jansson JH, et al. Interactions between fibrinolysis, lipoproteins and leptin related to a first myocardial infarction. Eur J Cardiovasc Prev Rehabil 2004; 11:33-40.
12. Mannucci PM, Bernardinelli L, Foco L, et al. Tissue plasminogen activator antigen is strongly associated with myocardial infarction in young women. J Thromb Haemost 2005; 3:280-286.
13. Zorio E, Castello R, Falco C, et al. Thrombin-activatable fibrinolysis inhibitor in young patients with myocardial infarction and its relationship with the fibrinolytic function and the protein C system. Br J Haematol 2003; 122:958-965.
14. Lundblad D, Dinesen B, Rautio A, et al. Low level of tissue plasminogen activator activity in nondiabetic patients with a first myocardial infarction. J Intern Med 2005; 258:13-20.
15. Johansson L, Jansson JH, Boman K, et al. Tissue plasminogen activator, plasminogen activator inhibitor-1, and tissue plasminogen activator/plasminogen activator inhibitor-1 complex as risk factors for the development of a first stroke. Stroke 2000; 31:26-32.
16. Jood K, Ladenvall P, Tjarnlund-Wolf A, et al. Fibrinolytic gene polymorphism and ischemic stroke. Stroke 2005; 36:2077-2081.
17. Smith A, Patterson C, Yarnell J, et al. Which hemostatic markers add to the predictive value of conventional risk factors for coronary heart disease and ischemic stroke? The Caerphilly Study. Circulation 2005; 112:3080-3087.
18. Ladenvall P, Wall U, Jern S, et al. Identification of eight novel single-nucleotide polymorphisms at human tissue-type plasminogen activator (t-PA) locus: association with vascular t-PA release in vivo. Thromb Haemost 2000; 84:150-155.
19. Ladenvall P, Johansson L, Jansson JH, et al. Tissue-type plasminogen activator -7,351C/T enhancer polymorphism is associated with a first myocardial infarction. Thromb Haemost 2002; 87:105-109.
20. Ladenvall P, Nilsson S, Jood K, et al. Genetic variation at the human tissue-type plasminogen activator (tPA) locus: haplotypes and analysis of association to plasma levels of tPA. Eur J Hum Genet 2003; 11:603-610.
21. Jannes J, Hamilton-Bruce MA, Pilotto L, et al. Tissue plasminogen activator - 7351C/T enhancer polymorphism is a risk factor for lacunar stroke. Stroke 2004; 35:1090-1094.
22. Booth NA. Fibrinolysis and thrombosis. Baillieres Best Pract Res Clin Haematol 1999; 12:423-433.
23. Folsom AR, Cushman M, Heckbert SR, et al. Prospective study of fibrinolytic markers and venous thromboembolism. J Clin Epidemiol 2003; 56:598-603.
24. Sartori MT, Wiman B, Vettore S, et al. 4G/5G polymorphism of PAI-1 gene promoter and fibrinolytic capacity in patients with deep vein thrombosis. Thromb Haemost 1998; 80:956-960.
25. Bombeli T, Jutzi M, De CE, et al. In patients with deep-vein thrombosis elevated levels of factor VIII correlate only with von Willebrand factor but not other endothelial cell-derived coagulation and fibrinolysis proteins. Blood Coagul Fibrinolysis 2002; 13:577-581.
26. Swiatkiewicz A, Jurkowski P, Kotschy M, et al. Level of antithrombin III, protein C, protein S and other selected parameters of coagulation and fibrinolysis in the blood of the patients with recurrent deep venous thrombosis. Med Sci Monit 2002; 8:CR263-CR268.
27. Asselbergs FW, Williams SM, Hebert PR, et al. The gender-specific role of polymorphisms from the fibrinolytic, rennin-angiotensin, and bradykinin systems in determining plasma t-PA and PAI-1 levels. Thromb Haemost 2006; 96:471-477.
28. Ye Z, Liu EH, Higgins JP, et al. Seven haemostatic gene polymorphisms in coronary disease: meta-analysis of 66,155 cases and 91,307 controls. Lancet 2006; 367:651-658. A metaanalysis on the association between seven polymorphisms in coagulation factors and platelet receptors and coronary artery disease showing that only the prothrombin 20210A variant and factor V Leiden form a mild risk factor for arterial thrombosis, whereas factor VII G10976A, PAI-1 4G/5G, and GPIa C807T, GPIbalpha T[-5]C, GPIIIa C1565T were not related to coronary artery disease.
29. Wiman B, Andersson T, Hallqvist J, et al. Plasma levels of tissue plasminogen activator/plasminogen activator inhibitor-1 complex and von Willebrand factor are significant risk markers for recurrent myocardial infarction in the Stockholm Heart Epidemiology Program (SHEEP) study. Arterioscler Thromb Vasc Biol 2000; 20:2019-2023.
30. Cushman M, Lemaitre RN, Kuller LH, et al. Fibrinolytic activation markers predict myocardial infarction in the elderly. The Cardiovascular Health Study. Arterioscler Thromb Vasc Biol 1999; 19:493-498.
31. Alessi MC, Juhan-Vague I. PAI-1 and the metabolic syndrome: links, causes, and consequences. Arterioscler Thromb Vasc Biol 2006; 26:2200-2207. This review clearly explains why PAI-1 can be considered as a component of the metabolic syndrome, and reveals novel links between PAI-1, the metabolic syndrome, and cardiovascular disease.
32. Takazoe K, Ogawa H, Yasue H, et al. Increased plasminogen activator inhibitor activity and diabetes predict subsequent coronary events in patients with angina pectoris. Ann Med 2001; 33:206-212.
33. Iacoviello L, Burzotta F, Di CA, et al. The 4G/5G polymorphism of PAI-1 promoter gene and the risk of myocardial infarction: a meta-analysis. Thromb Haemost 1998; 80:1029-1030.
34. Crainich P, Jenny NS, Tang Z, et al. Lack of association of the plasminogen activator inhibitor-1 4G/5G promoter polymorphism with cardiovascular disease in the elderly. J Thromb Haemost 2003; 1:1799-1804.
35. van Goor ML, Garcia EG, Leebeek F, et al. The plasminogen activator inhibitor (PAI-1) 4G/5G promoter polymorphism and PAI-1 levels in ischemic stroke: a case-control study. Thromb Haemost 2005; 93:92-96.
36. Hindorff LA, Schwartz SM, Siscovick DS, et al. The association of PAI-1 promoter 4G/5G insertion/deletion polymorphism with myocardial infarction and stroke in young women. J Cardiovasc Risk 2002; 9:131-137.
37. Wiklund PG, Nilsson L, Ardnor SN, et al. Plasminogen activator inhibitor-1 4G/5G polymorphism and risk of stroke: replicated findings in two nested case-control studies based on independent cohorts. Stroke 2005; 36:1661-1665.
38. Reiner AP, Schwartz SM, Frank MB, et al. Polymorphisms of coagulation factor XIII subunit A and risk of nonfatal hemorrhagic stroke in young white women. Stroke 2001; 32:2580-2586.
39. Hoekstra T, Geleijnse JM, Kluft C, et al. 4G/4G genotype of PAI-1 gene is associated with reduced risk of stroke in elderly. Stroke 2003; 34:2822-2828.
40. Elbaz A, Cambien F, Amarenco P. Plasminogen activator inhibitor genotype and brain infarction. Circulation 2001; 103:e13-e14.
41. Petrovic D, Milanez T, Kobal J, et al. Prothrombotic gene polymorphisms and atherothrombotic cerebral infarction. Acta Neurol Scand 2003; 108:109-113.
42. Heymans S, Luttun A, Nuyens D, et al. Inhibition of plasminogen activators or matrix metalloproteinases prevents cardiac rupture but impairs therapeutic angiogenesis and causes cardiac failure. Nat Med 1999; 5:1135-1142.
43. Melchor JP, Strickland S. Tissue plasminogen activator in central nervous system physiology and pathology. Thromb Haemost 2005; 93:655-660.
44. van Tilburg NH, Rosendaal FR, Bertina RM. Thrombin activatable fibrinolysis inhibitor and the risk for deep vein thrombosis. Blood 2000; 95:2855-2859.
45. Verdu J, Marco P, Benlloch S, et al. Thrombin activatable fibrinolysis inhibitor (TAFI) polymorphisms and plasma TAFI levels measured with an ELISA insensitive to isoforms in patients with venous thromboembolic disease (VTD). Thromb Haemost 2006; 95:585-586.
46. Eichinger S, Schonauer V, Weltermann A, et al. Thrombin-activatable fibrinolysis inhibitor and the risk for recurrent venous thromboembolism. Blood 2004; 103:3773-3776.
47. Martini CH, Brandts A, de Bruijne EL, et al. The effect of genetic variants in the thrombin activatable fibrinolysis inhibitor (TAFI) gene on TAFI-antigen levels, clot lysis time and the risk of venous thrombosis. Br J Haematol 2006; 134:92-94.
48. Morange PE, Juhan-Vague I, Scarabin PY, et al. Association between TAFI antigen and Ala147Thr polymorphism of the TAFI gene and the angina pectoris incidence. The PRIME Study (Prospective Epidemiological Study of MI). Thromb Haemost 2003; 89:554-560.
49. Leebeek FW, Goor MP, Guimaraes AH, et al. High functional levels of thrombin-activatable fibrinolysis inhibitor are associated with an increased risk of first ischemic stroke. J Thromb Haemost 2005; 3:2211-2218.
50. Henry M, Aubert H, Morange PE, et al. Identification of polymorphisms in the promoter and the 3′ region of the TAFI gene: evidence that plasma TAFI antigen levels are strongly genetically controlled. Blood 2001; 97:2053-2058.
51. Brouwers GJ, Vos HL, Leebeek FW, et al. A novel, possibly functional, single nucleotide polymorphism in the coding region of the thrombin-activatable fibrinolysis inhibitor (TAFI) gene is also associated with TAFI levels. Blood 2001; 98:1992-1993.
52. Franco RF, Fagundes MG, Meijers JC, et al. Identification of polymorphisms in the 5′-untranslated region of the TAFI gene: relationship with plasma TAFI levels and risk of venous thrombosis. Haematologica 2001; 86:510-517.
53. Frere C, Morange PE, Saut N, et al. Quantification of thrombin activatable fibrinolysis inhibitor (TAFI) gene polymorphism effects on plasma levels of TAFI measured with assays insensitive to isoform-dependent artefact. Thromb Haemost 2005; 94:373-379.
54. Schneider M, Boffa M, Stewart R, et al. Two naturally occurring variants of TAFI (Thr-325 and Ile-325) differ substantially with respect to thermal stability and antifibrinolytic activity of the enzyme. J Biol Chem 2002; 277:1021-1030.
55. Morange PE, Tregouet DA, Frere C, et al. TAFI gene haplotypes, TAFI plasma levels and future risk of coronary heart disease: the PRIME Study. J Thromb Haemost 2005; 3:1503-1510.
56. Juhan-Vague I, Morange PE, Aubert H, et al. Plasma thrombin-activatable fibrinolysis inhibitor antigen concentration and genotype in relation to myocardial infarction in the north and south of Europe. Arterioscler Thromb Vasc Biol 2002; 22:867-873.
57. Gils A, Alessi MC, Brouwers E, et al. Development of a genotype 325-specific proCPU/TAFI ELISA. Arterioscler Thromb Vasc Biol 2003; 23:1122-1127.
58. Myles T, Nishimura T, Yun TH, et al. Thrombin activatable fibrinolysis inhibitor, a potential regulator of vascular inflammation. J Biol Chem 2003; 278:51059-51067.
59. Bouma BN, Mosnier LO. Thrombin activatable fibrinolysis inhibitor (TAFI) at the interface between coagulation and fibrinolysis. Pathophysiol Haemost Thromb 2003; 33:375-381.
60. Lisman T, Leebeek FW, Mosnier LO, et al. Thrombin-activatable fibrinolysis inhibitor deficiency in cirrhosis is not associated with increased plasma fibrinolysis. Gastroenterology 2001; 121:131-139.
61. Leebeek FWG, Kock EL, Guimaraes AH, et al. Evidence for an enhanced fibrinolytic capacity in liver cirrhosis measured with a new global fibrinolysis test in whole blood. ASH Annual Meeting Abstracts 2006; 108:1627.
62. Prins MH, Hirsh J. A critical review of the evidence supporting a relationship between impaired fibrinolytic activity and venous thromboembolism. Arch Intern Med 1991; 151:1721-1731.
63. Lisman T, de Groot PG, Meijers JC, et al. Reduced plasma fibrinolytic potential is a risk factor for venous thrombosis. Blood 2005; 105:1102-1105.
64. Meltzer ME, Doggen CJM, de Groot PG, et al. Hypofibrinolysis as a risk factor for venous thrombosis. ASH Annual Meeting Abstracts 2006; 108:272.
65. Meade TW, Ruddock V, Stirling Y, et al. Fibrinolytic activity, clotting factors, and long-term incidence of ischaemic heart disease in the Northwick Park Heart Study. Lancet 1993; 342:1076-1079.
66. Meade TW, Cooper JA, Chakrabarti R, et al. Fibrinolytic activity and clotting factors in ischaemic heart disease in women. BMJ 1996; 312:1581.